MM-derived exosomes promote M2 macrophage polarization and immunosuppressive microenvironment: therapeutic opportunities [0.03%]
巨噬细胞源外泌体促进M2型极化和免疫抑制微环境：治疗机会
Qi Li,Yilei Shi,Wenzhuo Zhuang et al.
Qi Li et al.
Multiple myeloma (MM) progression involves extensive immunosuppressive remodeling of the bone marrow microenvironment. In this study, we performed a comprehensive mass spectrometry-based proteomic analysis of exosomes derived from MM cells ...
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin [0.03%]
一线 Brentuximab Vedotin 治疗后复发或难治性经典型霍奇金淋巴瘤患者的结局
Shin Yeu Ong,Lu Chen,Jomel Meeko Manzano et al.
Shin Yeu Ong et al.
Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies ...
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma [0.03%]
自体移植前疾病状态对复发/难治性经典型霍奇金淋巴瘤移植后 Brentuximab Vedotin 维持疗效的影响
Sanjal H Desai,Susan M Geyer,Levi Pederson et al.
Sanjal H Desai et al.
Patients with classic Hodgkin lymphoma (cHL) with primary refractory disease, early relapse, or extranodal disease have a higher risk of relapse after salvage therapy and autologous stem cell transplant (ASCT). Post-ASCT brentuximab vedotin...
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma [0.03%]
自体干细胞移植治疗多发性骨髓瘤后继发性血液系统恶性肿瘤的特点和结局
Binoy Yohannan,Benjamin W Langworthy,Lindsey E Turner et al.
Binoy Yohannan et al.
Autologous stem cell transplantation (auto-SCT) remains an important pillar in multiple myeloma (MM) therapy; however, there is an increased risk of developing second primary malignancy including second hematological malignancy (SHM). We pe...
Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation [0.03%]
维奈克拉联合强化疗作为FLT3-ITD突变新诊断AML的诱导化疗
Yuyu Liu,Guanchen Bai,Xingli Zhao et al.
Yuyu Liu et al.
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients [0.03%]
EMN12/HOVON-129初治多发性骨髓瘤移植适格队列患者的长期随访研究：首次聚焦浆细胞白血病患者
Niels W C J van de Donk,Fredrik Schjesvold,Bronno van der Holt et al.
Niels W C J van de Donk et al.
Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML [0.03%]
TP53基因突变型急性髓系白血病患者中集束化化疗的预后影响
Laurène Fenwarth,Loïc Vasseur,Nicolas Duployez et al.
Laurène Fenwarth et al.
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study [0.03%]
一种新型JAK/ROCK抑制剂rovadicitinib对骨髓纤维化患者的疗效：一项针对受试者的I期临床试验及前期研究
Zefeng Xu,Jinqin Liu,Zhenya Hong et al.
Zefeng Xu et al.
Clonal hematopoiesis of indeterminate potential in high grade B-cell lymphomas: clinicobiological associations and further insight with single-cell multiomics analysis [0.03%]
高B细胞淋巴瘤中不确定潜能的克隆性造血：临床生物学关联及单细胞多组学分析进一步揭示了什么
Caroline Hesselager,Peter Hollander,Emma Pettersson et al.
Caroline Hesselager et al.
Florian Van Oers,Donovan Flumens,Simon Haentjens et al.
Florian Van Oers et al.
Acute myeloid leukemia (AML) remains a highly aggressive malignancy with limited therapeutic options and poor long-term survival. A major barrier to curative treatment is the persistence of leukemic stem cells (LSCs), a chemo-resistant popu...